FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 阿里健康信息技術有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00241 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.01 HKD | | | 200,000,000 | | 增加 / 減少 (-) | | | | 0 | | HKD | | | 0 | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.01 ...

Group 1 - The core point of the article highlights the recent reduction in holdings of Alibaba Health (00241.HK) by southbound funds, with a total net reduction of 15.94 million shares over the last five trading days and 35.13 million shares over the last 20 trading days [1][2] - As of now, southbound funds hold 1.736 billion shares of Alibaba Health, accounting for 10.76% of the company's total issued ordinary shares [1][2] - The daily changes in shareholdings show a consistent trend of reduction, with the most recent decrease being 316,000 shares on October 27, 2025, representing a change of -0.02% [2] Group 2 - Alibaba Health Information Technology Co., Ltd. is a holding company providing industrial internet solutions for the healthcare and pharmaceutical industry, serving as Alibaba's flagship platform in the health sector [2] - The company primarily engages in the sales of pharmaceutical health products, operates e-commerce platforms for pharmaceuticals, and offers consumer healthcare services, leveraging technologies such as cloud computing and big data [2]

Group 1 - The Hang Seng Index rebounded, closing up 0.72%, with the internet sector leading the gains, followed by banking, industry, technology, and real estate sectors [1] - The internet sector saw a rise of 1.07%, with Meituan up 4.06%, Alibaba up 1.67%, Tencent Holdings up 1.52%, JD Group up 1.5%, and Baidu Group up 1.22%. However, companies like SenseTime, Bilibili, and Kingdee International experienced declines [3] - The banking sector opened strong and maintained a consolidation above the midline, closing up 0.88%, with Postal Savings Bank rising 4.59% and Minsheng Bank up 2.39% [3] Group 2 - The consumer sector rebounded, closing up 0.35%, with notable gains from companies like Chenzi Biological up 6.68%, Li Ning up 6.55%, and Sands China up 4.4% [3] - The healthcare sector opened low and saw a slight reversal near the end, closing down 1.31%, with CSPC Pharmaceutical down 2.96% and China Biopharmaceutical down 2.78% [3]

Core Viewpoint - The collaboration between the United Nations Population Fund and Alibaba Health aims to promote women's health through the initiative "Guard Her Health, Please Be Assured at This Moment" [1] Group 1: Initiative Overview - The initiative focuses on women's health as a core social development issue, emphasizing a comprehensive approach through service support, safety net construction, and educational reform [1] - Alibaba Health plans to leverage its platform responsibility to transform the initiative into tangible moments of assurance for women, promoting equality and health as fundamental aspects of women's lives [1] Group 2: Stakeholder Perspectives - The project director of the Love Xiaoya Fund highlights the need for societal attention to women's health, particularly in guiding adolescent girls on health knowledge and gender equality [1] - The marketing head of Tmall Health emphasizes the importance of ensuring every woman has access to safe and quality health products and services, focusing on comprehensive health development for women across all life stages [1] Group 3: Collaborative Goals - The initiative calls for a collective focus on women's health throughout their life cycle, advocating for public-private partnerships that combine the public sector's equity mission with the private sector's innovation and adaptability [1]

Core Viewpoint - Hong Kong technology stocks opened significantly higher, with the Hang Seng Technology Index rising nearly 4% [1] Group 1: Stock Performance - NetEase surged over 6% [1] - Ctrip Group, Baidu Group, and JD Group each increased by over 5% [1] - ASMPT, Alibaba, JD Health, Sunny Optical, NIO, Kuaishou, Haier Smart Home, and Bilibili all rose by over 4% [1] - SMIC, Hua Hong Semiconductor, Kingdee International, SenseTime, Horizon Robotics, Xpeng Motors, Meituan, BYD Electronics, Alibaba Health increased by over 3% [1] - Tencent saw a rise of 2.6% [1]

Group 1 - The United Nations Population Fund and Alibaba Health launched the "Guard Her Health, Please Be Assured at This Moment" initiative to promote women's health, coinciding with the 30th anniversary of the Fourth World Conference on Women held in Beijing [1][3] - The initiative emphasizes the importance of women's health for their full participation in social life, which in turn strengthens families, drives the economy, and shapes a more equal and prosperous future [1][3] - The National Health Commission of China highlighted significant achievements in women's health, including the inclusion of maternal transmission prevention of diseases like AIDS, syphilis, and hepatitis B in major public health service projects [3] Group 2 - From 2009 to 2024, China conducted free cervical cancer screenings for 342 million people and breast cancer screenings for 245 million people, with a central government investment of 3.01 billion yuan to assist women with health issues [3] - By June 2025, 18 provinces will provide free HPV vaccinations to approximately 5 million eligible girls annually, as part of government initiatives [3] - There is a growing awareness among mothers regarding their health, with an increase in online searches for health products related to postpartum recovery [3][4] Group 3 - The initiative calls for a focus on women's health throughout their life cycle and encourages public-private partnerships to combine the public sector's commitment to equity with the private sector's innovation and adaptability [4]

Core Viewpoint - The Hong Kong stock market experienced a significant decline in technology stocks, with the Hang Seng Technology Index dropping over 2% [1] Group 1: Market Performance - BYD Electronics fell by over 5%, while other notable declines included ASMPT, JD Health, SMIC, SenseTime-W, Kingdee International, Baidu, which all dropped over 3% [1] - Other companies such as Sunny Optical, Kingsoft, Huahong Semiconductor, Alibaba Health, Tencent Music, Alibaba, and Meituan saw declines exceeding 2% [1] Group 2: Stock Performance Data - BYD Electronics: -5.50% YTD change, market cap of 87.469 billion [2] - Horizon Robotics-W: -4.57% YTD change, market cap of 122.49 billion [2] - ASMPT: -3.74% YTD change, market cap of 26.6656 billion [2] - JD Health: -3.66% YTD change, market cap of 198.171 billion [2] - SMIC: -3.59% YTD change, market cap of 570.005 billion [2] - SenseTime-W: -3.21% YTD change, market cap of 93.204 billion [2] - Kingdee International: -3.46% YTD change, market cap of 52.461 billion [2] - Sunny Optical: -2.74% YTD change, market cap of 85.559 billion [2] - Kingsoft: -2.71% YTD change, market cap of 45.206 billion [2] - Huahong Semiconductor: -2.27% YTD change, market cap of 138.142 billion [2] - Alibaba Health: -2.27% YTD change, market cap of 97.232 billion [2] - Tencent Music-SW: -2.25% YTD change, market cap of 269.509 billion [2] - Alibaba-W: -2.23% YTD change, market cap of 3,010 billion [2] - Meituan-W: -2.23% YTD change, market cap of 590.049 billion [2]

Core Insights - The GLP-1 weight loss market is experiencing significant investment and growth, with a notable $600 million Series B funding for NewCo, a subsidiary of Heng Rui Pharmaceutical, indicating strong capital interest in the sector [3][4] - The focus has shifted from merely developing successful GLP-1 drugs to efficiently commercializing them, as evidenced by the increasing number of IPO filings and soaring stock prices of listed companies [3][4] - The competitive landscape is intensifying, with five GLP-1 injection products already approved in China and many more in development, leading to a need for effective commercialization strategies [4][8] Investment and Market Dynamics - The GLP-1 weight loss market is projected to exceed 30 billion by 2030, with e-commerce expected to capture over 50% of this market share [6][12] - Companies are increasingly turning to e-commerce platforms to enhance sales, as traditional hospital channels face regulatory and logistical challenges [5][8] - The shift towards consumer-focused marketing strategies is evident, with companies prioritizing consumer awareness and engagement over traditional prescription-based approaches [7][16] E-commerce Strategies - Major pharmaceutical companies are forming partnerships with e-commerce platforms to facilitate the sale of GLP-1 products, with notable collaborations between Novo Nordisk, Eli Lilly, and platforms like JD Health and Meituan [8][12] - Innovative marketing campaigns, such as "money-back guarantees" for weight loss, are being employed to attract consumers and drive sales [9][10] - The competitive advantage in e-commerce is increasingly tied to logistics capabilities, particularly cold chain logistics, which are essential for the distribution of GLP-1 injection products [16][17] Future Outlook - The industry is witnessing a rapid transformation, with a focus on creating a consumer-friendly environment for GLP-1 products, which were previously treated as prescription-only medications [7][8] - The potential for a billion-dollar market in GLP-1 products is anticipated, contingent on healthy competition and effective marketing strategies [17]

Core Insights - The GLP-1 weight loss market is experiencing significant investment and growth, with a notable $600 million Series B funding for NewCo, a subsidiary of Heng Rui Pharmaceutical, highlighting the industry's potential [1] - The focus has shifted from merely developing GLP-1 drugs to effectively commercializing them, as evidenced by the increasing number of IPO filings and soaring stock prices of companies in this sector [1] Investment Trends - Major investments are flowing into the GLP-1 market, with companies like NewCo receiving substantial funding [1] - Several companies, including Senwa Biotech and Chengyi Biotech, have filed for IPOs, indicating strong investor interest [1] Product Landscape - As of 2025, five GLP-1 injection products have been approved in China, with more in the pipeline, including those from Senwa Biotech and Heng Rui Pharmaceutical [2][6] - The approved products vary in administration frequency and weight loss efficacy, with some showing significant results over extended periods [2] Market Challenges - New GLP-1 products face hurdles in hospital sales due to strict prescription regulations and procurement limitations [3][6] - The market is transitioning towards e-commerce as a viable sales channel to overcome these challenges, with companies looking to leverage online platforms for broader consumer access [3][4] E-commerce Strategy - E-commerce is becoming a critical sales channel for GLP-1 products, with companies like Novo Nordisk and Eli Lilly beginning to embrace this shift [4][5] - By 2030, the GLP-1 market in the weight loss sector is projected to exceed 30 billion, with e-commerce expected to capture over 50% of this market [5] Consumer Engagement - The marketing approach has evolved from focusing on clinical data to enhancing consumer awareness and engagement, emphasizing the importance of user-friendly communication [5][6] - Companies are increasingly investing in promotional activities and partnerships with e-commerce platforms to drive consumer interest and sales [10][12] Competitive Landscape - The competition among e-commerce platforms is intensifying, with each platform leveraging its unique strengths to capture market share [13][14] - Cold chain logistics are becoming a crucial factor in the distribution of GLP-1 products, with companies like JD Health and Meituan Buy Medicine enhancing their capabilities to ensure product integrity [14] Future Outlook - The GLP-1 market is expected to grow rapidly, but the industry is cautious about maintaining healthy competition rather than descending into chaos [15][16]

智通财经APP获悉，美银证券发布研报称，预期阿里健康(00241)明年3月底止现财年业绩将超越市场共 识。该行上调公司现财年收入增长预测4个百分点至14%，经调整净利润增长预测上调10个百分点至 30%。该行上调阿里健康现财年及下财年经调整净利润预测8%，2024财年至2031财年预期自由现金流 年复合年增长率由42%上调至45%。对阿里健康目标价从5.5港元上调至6.56港元，重申"买入"评级。 该行指，阿里健康超预期业绩增长关键驱动因素包括618销售表现良好，母公司阿里巴巴-W(09988)在快 电商的投资加速淘宝天猫的流量并惠及阿里健康，包括年轻用户群流量增加、B2C电商交叉销售及更多 商家的广告支出。该行亦指，药品销售线上渗透率增加、商家及药品品牌广告支出上升并提振阿里健康 利润率，亦为业绩增长驱动因素。 ...